A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, With and Without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 2 and 3 Chronic Hepatitis C Subjects

Trial Profile

A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, With and Without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 2 and 3 Chronic Hepatitis C Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Daclatasvir (Primary) ; Peginterferon lambda-1a (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PRINCIPAL
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Sep 2016 Results analyzing HCV GT2 NS5A sequencing data from five clinical trials and one database (The Los Alamos hepatitis C sequence database) (n=426) published in the Journal of Antimicrobial Chemotherapy.
    • 30 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jun 2014 Planned End Date changed from 1 Dec 2014 to 1 Nov 2014as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top